Study of 68Gallium-FAPI46 PETCT Imaging to Evaluate Chronic Inflammatory and Fibrotic Diseases

What this Trial Is About

Researchers are exploring the potential use of the imaging agent 68Ga Ga-FAPI in PETCT scans for diagnosing and monitoring various chronic inflammatory and fibrotic diseases. This pilot study focuses on 13 different clinical conditions such as rheumatoid arthritis, liver fibrosis, and systemic lupus to assess whether this new radiotracer can improve disease evaluation compared to current methods. The study aims to gather initial data to guide further development and possible routine use of this imaging technique in these diseases. Participants receive a 68Ga Ga-FAPI PETCT scan in addition to their usual medical care. The imaging is performed either once at baseline or longitudinally at baseline and again at 3 and 6 months if their treatment is intensified at inclusion. This approach allows researchers to observe how the radiotracer behaves in different diseases and over time, helping to refine its clinical application. During the study, participants undergo PETCT scans to measure the intensity of the PET uptake and correlate these findings with pathology evaluations, biomarkers, functional parameters, and imaging characteristics at baseline, 3 months, and 6 months. This detailed assessment helps to understand the diagnostic value of 68Ga Ga-FAPI in chronic inflammatory and fibrotic conditions. The study runs until October 2028 and is conducted at a single center, with participants followed through these imaging and clinical evaluations.

68Gallium-FAPI46 PET/CT Imaging in Chronic Inflammatory and Fibrotic Diseases